Baillie Gifford acquired 14.2 Million Dexcom shares worth $1.21 Billion. That's 1.00% of their equity portfolio (25th largest holding). The investor owns 3.78% of the outstanding Dexcom stock. The first Dexcom trade was made in Q1 2013. Since then Baillie Gifford bought shares fifteen more times and sold shares on 32 occasions. The stake costed the investor $486 Million, netting the investor a gain of 149% so far.